Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought

Oncology Times - OncTimes Talk

コンテンツは Oncology Times によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Oncology Times またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

4M ago 4:31

MP3

Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden.

Furthermore, the study found a higher than previously reported negative interaction of PPI comedication on crystalline dasatinib bioavailability that may compromise clinical efficacy and risk CML disease progression.

The latest findings from the study were reported in a poster session at the 2024 ASCO Annual Meeting where Oncology Times reporter Peter Goodwin met up with Olof Harlin, PhD, of Xspray Pharma, based in Solna, near Stockholm, Sweden.

172 つのエピソード